Millennium, Sunesis Link For Cancer Drugs | April 11, 2011 Issue - Vol. 89 Issue 15 | Chemical & Engineering News
Volume 89 Issue 15 | p. 21 | Concentrates
Issue Date: April 11, 2011

Millennium, Sunesis Link For Cancer Drugs

Department: Business
Keywords: cancer, Raf, kinases, drug development

Millennium, the U.S. arm of Japanese drug firm Takeda, will pay Sunesis Pharmaceuticals $4 million up front and up to $60 million in milestones for two kinase inhibitors. Millennium gains vosaroxin, an oral, selective pan-Raf kinase inhibitor in Phase III trials to treat acute myeloid leukemia, and an undisclosed kinase inhibitor also being developed to treat cancer. Sunesis was developing the compounds with Biogen Idec, which is exiting oncology research.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society